AP NEWS

Diarrhea Pipeline Review, H2 2018 - Therapeutic Assessment of 32 Companies & Drug Pipelines - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Diarrhea - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Diarrhea - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Diarrhea (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diarrhea (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 8, 6, 1, 17 and 7 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 2 and 5 molecules, respectively.

Diarrhea (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Diarrhea - Overview Diarrhea - Therapeutics Development Diarrhea - Therapeutics Assessment Diarrhea - Companies Involved in Therapeutics Development Diarrhea - Drug Profiles Diarrhea - Dormant Projects Diarrhea - Discontinued Products Diarrhea - Product Development Milestones Appendix

Companies Mentioned

Aegis Therapeutics LLC Akthelia Pharmaceuticals Ltd Albireo Pharma Inc Allergan Plc Ardelyx Inc AzurRx BioPharma Inc Bharat Biotech Ltd Chongqing Zhifei Biological Products Co Ltd Cosmo Pharmaceuticals NV DiscoveryBiomed Inc Ferring International Center SA GP Pharm SA Kuhnil Pharmaceutical Co Ltd Metacrine Inc Miyarisan Pharmaceutical Company Ltd Napo Pharmaceuticals Inc Nippon Shinyaku Co Ltd Novartis AG Pfizer Inc Prokarium Ltd Protagonist Therapeutics Inc RaQualia Pharma Inc RedHill Biopharma Ltd RxBio Inc Scandinavian Biopharma Holding AB Sublimity Therapeutics Ltd Summit Therapeutics Plc Synthetic Biologics Inc Syntiron LLC Tasly Pharmaceutical Group Co Ltd Wuhan Institute of Biological Products Co Ltd Zealand Pharma AS For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rg9z4q/diarrhea_pipeline?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925006181/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 04:44 PM/DISC: 09/25/2018 04:44 PM

http://www.businesswire.com/news/home/20180925006181/en

AP RADIO
Update hourly